Simplification of adenophostin a defines a minimal structure for potent glucopyranoside-based mimics of D-myo-inositol 1,4,5-trisphosphate

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 3, 1999, Pages 453-458

  Marwood, Rachel D ^a   Riley, Andrew M ^a   Correa, Vanessa ^b   Taylor, Colin W ^b   Potter, Barry V L ^a  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 O [3 HYDROXYTETRAHYDROFURAN 4 YL]ALPHA DEXTRO GLUCOPYRANOSIDE 3,4,3' TRIPHOSPHATE; CALCIUM CHANNEL STIMULATING AGENT; INOSITOL 1,4,5 TRISPHOSPHATE DERIVATIVE; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM MOBILIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; OPTICAL ROTATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADENOSINE; ANIMALS; CALCIUM; CARBOHYDRATE CONFORMATION; CELLS, CULTURED; FURANS; GLUCOSEPHOSPHATES; GLYCOSIDES; INOSITOL 1,4,5-TRISPHOSPHATE; LIVER; MOLECULAR MIMICRY; RATS;

EID: 0033535151     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00006-2     Document Type: Article

References (20)

1. Berridge, M.J. Nature (London) 1993, 361, 315-325.
2. Potter, B.V.L.; Lampe, D. Angew. Chem. Int. Ed. Engl. 1995 34, 1972-1993.
3. Takahashi, M.; Kagasaki, T.; Hosoya, T.; Takahashi, S. J. Antibiot. 1993, 46, 1643-1647.
4. Takahashi, S.; Kinoshita, T.; Takahashi, M. J. Antibiot. 1994, 47, 95-100;
5. Takahashi, M.; Tanzawa, K.; Takahashi, S. J. Biol. Chem. 1994, 269, 369-372.
6. Hirota, J.; Michikawa, T.; Miyawaki, A.; Takahashi, M.; Tanzawa, K.; Okura, I.; Furuichi, T.; Miksoshiba, K. FEBS Letters 1995, 248-252.
7. 6. Jenkins, D.J.; Potter, B.V.L. J. Chem. Soc. Chem. Commun. 1995, 1169-1170; Jenkins, D.J.; Potter, B.V.L. Carbohydr. Res. 1996, 169-182.
8. Jenkins, D.J.; Potter, B.V.L. J. Chem. Soc. Chem. Commun. 1995, 1169-1170; Jenkins, D.J.; Potter, B.V.L. Carbohydr. Res. 1996, 169-182.
9. Wilcox, R.A.; Erneux, C.; Primrose, W.U.; Gigg, R., Nahorski, S.R. Mol. Pharmacol. 1995, 47, 1204-1211.
10. 2+ release from permeabilised hepatocytes.
11. Murphy, C.T.; Riley, A.M.; Lindley, C.J.; Jenkins, D.J.; Westwick, J.; Potter, B.V.L. Mol. Pharmacol. 1997, 52, 741-748.
12. Marchant, J.S.; Beecroft, M.D.; Riley, A.M.; Jenkins, D.J.; Marwood, R.D.; Taylor, C.W.; Potter, B.V.L. Biochemistry 1997, 36, 12780-12790.
13. Jenkins, D.J.; Marwood, R.D.; Potter, B.V.L. J. Chem. Soc. Chem. Commun. 1997, 449-450.
14. Johansson, R.; Samuelsson, B. J. Chem. Soc. Perkin Trans 1 1984, 2371-2374.
15. AB 11.5 Hz), 5.50 (1 H, td, J 4.8 Hz, 2.6 Hz), 6.84-6.89 (2 H, m), 7.22-7.28 (2 H, m).
16. 3).
17. 23 -26.5 (c 1, MeOH). This identifies (-)-12 as (-)-(3R,45)-4-benzyloxytetrahydrofuran-3-ol.
18. Watanabe, Y.; Nakamoto, C.; Yamamoto, T.; Ozaki, S. Tetrahedron 1994, 50, 6523-6536.
19. HP 9.8 Hz).
20. 2+ release was given, and 7 could therefore not be designated as an agonist or antagonist.